Rho-kinase has been identiˆed as one of the eŠectors of the small GTP-binding protein Rho. Accumulating evidence has demonstrated that the Rho/Rho-kinase pathway plays an important role in various cellular functions, not only in vascular smooth muscle cell (VSMC) contraction but also in VSMC proliferation, cell migration, and gene expression. Two isoforms of Rho-kinase encoded by two diŠerent genes have been identiˆed: ROCK1 and ROCK2. These isoforms are ubiquitously expressed, but with preferential expression of ROCK2 in the brain and skeletal muscle. The expression of Rho-kinase itself is mediated by the protein kinase C/NF-kB pathway with an inhibitory and stimulatory modulation by estrogen and nicotine, respectively. At the cellular level, Rho-kinase mediates VSMC contraction, stimulates VSMC proliferation and migration, and enhances in‰ammatory cell motility. Rho-kinase also upregulates various molecules that accelerate in‰ammation/oxidative stress, thrombus formation, andˆbrosis, while it downregulates endothelial nitric oxide synthase and inhibits insulin signaling. Rho-kinase activity regulates major morphogenetic events during embryonic development through cell migration, diŠerentiation, and axis formation. In animal and clinical studies, Rho-kinase has been shown to be substantially involved in the pathogenesis of vasospasm, arteriosclerosis, hypertension, pulmonary hypertension, and ischemia/reperfusion injury. Fasudil, a selective Rho-kinase inhibitor developed in Japan, is eŠective for the treatment of a wide range of cardiovascular diseases, with reasonable safety. Thus Rhokinase is an important therapeutic target in cardiovascular medicine. This review summarizes the recent progress in the study of Rho-kinase and addresses future perspectives of Rho-kinase inhibitors.
はじめに
After intracoronary nitroglycerin (10 mg/kg), mild stenotic lesion was noted at the IL-1b-treated site (arrow) (A), where intracoronary serotonin (10 mg/kg) repeatedly induced coronary hyperconstriction (B). This serotonin-induced coronary hyperconstriction was dose-dependently inhibited by pretreatment with intracoronary hydroxyfasudil (10, 30, and 100 mg/kg) (C-E). Note that neointimal formation is suppressed at AdDNRhoK site despite disruption of internal elastic lamina (shown by arrows). Coronary stenotic lesions persisted at the IL-1b-treated coronary segments in the control group, whereas they were signiˆcantly reduced in the fasudil group after the 8-week treatment with fasudil followed by a 1-week washout period. RT-PCR analysis for Rho-kinase mRNA expression (A) and Western blot analysis for MBS phosphorylations (MBS-P) (B) in isolated carotid arteries. 
